A New Drug for Advanced Liver Cancer Treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new targeted therapy called donafenib for patients with advanced hepatocellular carcinoma (liver cancer) that cannot be surgically removed. The drug may help slow or shrink the cancer in patients who haven't received systemic chemotherapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hepatocellular carcinoma (liver cancer) that is either inoperable or has spread to other parts of your body
- You have not received systemic chemotherapy (whole-body cancer treatment) for advanced disease, though prior local treatments like surgery or radiation are allowed if done long enough ago
- Your liver function is reasonably well-preserved (Child-Pugh score of 7 or less, meaning your liver can still handle medications)
- Your blood counts and kidney/liver function tests meet specific minimums, and you are generally in good health (ECOG performance status 0 or 1)
- You completed any recent cancer treatments, radiotherapy, or ablation at least 4 weeks before enrolling
- You have at least one tumor lesion that can be measured on imaging to track whether the drug is working
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a four-drug combination (epalrestat, HAIC chemotherapy, donafenib, and tislelizumab) as a first treatment for patients with advanced liver cancer that cannot be removed by surgery, who also have diabetes. The goal is to shrink the cancer while managing nerve damage from diabetes.
This study looks at combining donafenib (a targeted therapy) with an immunotherapy drug (PD-1/L1 inhibitor) and either TACE or HAIC (two types of minimally invasive treatments for liver tumors) as a first treatment for people with liver cancer that cannot be removed by surgery. It aims to see how well this combination works and how safe it is.
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
This trial tests a combination of the targeted drug donafenib, immunotherapy, and local treatments (like chemo delivered directly to the liver) for people with liver cancer that cannot be removed by surgery and has stopped responding to previous treatments. The goal is to see if this new combination can shrink tumors or slow the disease.
This study tests a new way to treat liver cancer that can't be removed with surgery. It combines a targeted drug (donafenib) with a procedure called E-TACE, which delivers chemotherapy directly to the tumor. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of treatments—chemotherapy delivered through the liver artery (HAIC), a targeted drug (donafenib), and an immunotherapy (sintilimab)—given before and after surgery for liver cancer that has a high chance of coming back. The goal is to see if this approach can lower the risk of recurrence.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.